Akademik Veri Yönetim Sistemi
Indian Journal of Hematology and Blood Transfusion, 2026 (SCI-Expanded, Scopus)
This retrospective study aimed to determine the factors affecting the survival of myeloma patients with extramedullary disease (EMD). The data of 99 patients followed up at a single centre between 2010 and 2022 was analyzed. EMD was detected in 92 patients at diagnosis (primary EMD) and seven at relapse (secondary EMD). Bone-related extramedullary involvement (EM-B) was observed in 72 patients, while 27 had extraosseous extramedullary involvement (EM-E). The median follow-up period of patients was 33 months (range: 2-120 months). PET/CT was used to diagnose EMD in 75 patients, and single-site extramedullary involvement was detected in 56 patients. The most common induction regimen was bortezomib-cyclophosphamide-dexamethasone (VCD), given to 35 patients. In addition, 38 patients received autologous stem cell transplantation (ASCT). Advanced ISS stage (OS HR: 2.42; 95% CI: 1.12–5.24; p = 0.024), secondary EMD (PFS HR: 2.87; 95% CI: 1.26–6.56; p = 0.013), light chain disease (OS median survival 24 months / 78 months, p = 0.049), multiple extramedullary involvement site (PFS HR: 1.33; 95% CI: 0.70–2.53; p = NS), high-risk cytogenetic features (OS HR: 1.88; 95% CI: 0.63–5.63; p = NS), elevated serum creatinine (OS HR: 1.22; 95% CI: 1.01–1.48; p = 0.043) and elevated serum Beta-2-Microglobulin (OS HR: 2.46; 95% CI: 1.15–5.26; p = 0.020) negatively impacted survival. The median PFS was 49 months in the EM-B group and 63 months in the EM-E group (p = 0.209). The induction regimen groups showed similar survival outcomes, whereas ASCT was significantly related to increased overall survival (OS HR: 0.28; 95% CI: 0.12–0.61; p = 0.004).